View our latest publications.
	Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge Nature Medicine 15, 293 - 299 (2009) (Click here for full text)
Cowpox Virus Inhibits the Transporter Associated with Antigen Processing to Evade T Cell Recognition Cell Host & Microbe, Volume 6, Issue 5, 433-445, 19 November 2009 (Click here for PubMed link)
	Evasion of CD8+ T Cells Is Critical for Superinfection by Cytomegalovirus Science 2 April 2010: Vol. 328. no. 5974, pp. 102 - 106 (Click here for full text)
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine Nature 26 May 2011 / Vol 473 / Issue No 7348 Page 523 (Click here for PubMed link)

VGTI NEWS LINKS

OHSU research helps explain why an AIDS vaccine has been so difficult to develop
Research highlights why new methods developed at OHSU may be the most promising avenues for fighting the disease. For decades, a successful HIV vaccine has been the Holy Grail for researchers around the globe. Yet despite years of research and millions of dollars of investment, that goal has still yet to be achieved. Recent research by Oregon Health & Science University scientists explains a decades-old mystery as to why slightly weakened versions of the monkey AIDS virus were able to prevent subsequent infection with the fully virulent strain, but were too risky for human use, and why severely compromised or completely inactivated versions of the virus were not effective at all. READ MORE

OHSU receives additional Grand Challenges Explorations funding of novel approach to develop AIDS vaccine that blocks infection
Oregon Health & Science University researchers have received additional funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation, to conduct AIDS vaccine research. The funding enables individuals worldwide to test unorthodox ideas that address persistent health and development challenges. OHSU’s research funded through a $999,998 grant will take place at the Vaccine and Gene Therapy Institute on OHSU’s West Campus in Beaverton, Ore., and will be led by assistant scientist Jonah Sacha, Ph.D. READ MORE

OHSU Vaccine and Gene Therapy Institute receives Grant for AIDS Vaccine Development
Research supported by Bill & Melinda Gates Foundation will accelerate OHSU’s promising vaccine candidate.
OHSU Vaccine and Gene Therapy Institute receives Grant for AIDS Vaccine Development Researchers at Oregon Health & Science University’s Vaccine and Gene Therapy Institute have been awarded an $8 million grant from the Bill & Melinda Gates Foundation to further develop a promising HIV vaccine candidate to combat the worldwide AIDS epidemic. READ MORE

Non-Human Primate Studies Reveal Promising Vaccine Approach for HIV
Research conducted at Oregon Health & Science University's Vaccine and Gene Therapy Institute (VGTI) has developed a vaccine candidate in non-human primates that may eventually lead to a vaccine against Human Immunodeficiency Virus (HIV). Details of this advance are published in the advance online edition of the journal Nature. The paper will also be published in an upcoming print addition of the journal. READ MORE

Contact us by e-mail at vgti@ohsu.edu or by phone at (503) 418-2700

All text copyright © Vaccine and Gene Therapy Institute, 2001-12